FDA
-
-
-
-
-
-
-
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
-
-
-
-
-
-
-
Coya Therapeutics study shows immune dysfunction in dementia patients
-
-
-
-
-
-
-
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
-
-
-
-
-
-
-
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
-
-
-
-
-
-
-
Coya Therapeutics announces proposed public stock offering
-
-
-
-
-
-
-
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
-
-
-
-
-
-
-
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

